Move aside, small-molecule drugs for common diseases. Three biologic medicines initially developed to treat rheumatoid arthritis—a joint disorder that afflicts just 1% of the population worldwide—are on track to top the sales charts this year. According to forecasts compiled by Thomson Reuters's pharmaceutical intelligence unit, Humira (adalimumab) and two comparable antibodies that also target tumor necrosis factor-alpha, a cytokine involved in rheumatoid arthritis, will lead the list.
The trio will topple the cholesterol drug Lipitor (atorvastatin) and the blood thinner Plavix (clopidogrel) to become the world's top-selling medicines in 2012. Despite the smaller patient populations targeted by these biologics, the higher prices they demand can still translate into a sizeable market share, explains analyst Saurabh Aggarwal, principal of Novel Health Strategies, a life sciences consulting firm based in Bethesda, Maryland. “The pricing is a big factor that's driving the high sales in these products,” he says.
Rights and permissions
About this article
Cite this article
Biologic drugs set to top 2012 sales. Nat Med 18, 636 (2012). https://doi.org/10.1038/nm0512-636a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0512-636a
This article is cited by
-
A BioDesign Approach to Obtain High Yields of Biosimilars by Anti-apoptotic Cell Engineering: a Case Study to Increase the Production Yield of Anti-TNF Alpha Producing Recombinant CHO Cells
Applied Biochemistry and Biotechnology (2018)
-
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Nature Chemistry (2013)